miR-520a-5p induces docetaxel resistance in prostate cancer cells by regulating aerobic glycolysis

Xie Jianyun; Chen Weidong

doi:10.13406/j.cnki.cyxb.003314

您当前的位置：

首页 >

文章列表页 >

miR-520a-5p induces docetaxel resistance in prostate cancer cells by regulating aerobic glycolysis

Carcinoma of prostate | 更新时间：2025-10-21

- miR-520a-5p induces docetaxel resistance in prostate cancer cells by regulating aerobic glycolysis
- Journal of Chongqing Medical University Vol. 48, Issue 8, Pages: 909-915(2023)
- 作者机构：
  
  福建中医药大学附属人民医院泌尿外科，福州 350004
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003314
  CLC： R737.25
- Received：30 May 2023，
  
  Revised：2023-07-26，
  
  Accepted：28 August 2023，
  
  Published：28 August 2023
- 稿件说明：
移动端阅览
谢剑云,陈伟东.miR-520a-5p通过调控有氧糖酵解诱导前列腺癌细胞多西他赛耐药[J].重庆医科大学学报,2023,48(8):909-915.

Xie Jianyun,Chen Weidong.miR-520a-5p induces docetaxel resistance in prostate cancer cells by regulating aerobic glycolysis[J].Journal of Chongqing Medical University,2023,48(8):909-915.
谢剑云,陈伟东.miR-520a-5p通过调控有氧糖酵解诱导前列腺癌细胞多西他赛耐药[J].重庆医科大学学报,2023,48(8):909-915. DOI： 10.13406/j.cnki.cyxb.003314.

Xie Jianyun,Chen Weidong.miR-520a-5p induces docetaxel resistance in prostate cancer cells by regulating aerobic glycolysis[J].Journal of Chongqing Medical University,2023,48(8):909-915. DOI： 10.13406/j.cnki.cyxb.003314.

摘要

目的

探索miR-520a-5p对前列腺癌增殖能力和多西他赛耐药性的影响及其作用机制。

方法

使用RT-qPCR检测PC-3/DU145前列腺癌细胞及RWPE-1前列腺正常上皮细胞中miR-520a-5p表达水平；使用免疫印迹检测miR-520a-5p是否调控糖酵解关键酶己糖激酶2（hexokinase 2，HK2）和磷酸果糖激酶（phosphofructokinase，PFKM）表达水平；使用CCK-8实验检测miR-520a-5p对前列腺癌细胞增殖能力和多西他赛耐药性的影响；使用ELISA评估培养上清中葡萄糖消耗水平和乳酸生成水平。依据转染物的不同，将所有细胞分成4组：minic组、minic NC组、inhibitor组、inhibitor NC组。

结果

miR-520a-5p在前列腺癌细胞中表达下调（

0.001）。与minic NC组比较，minic组可显著降低PC-3和DU145前列腺癌细胞的增殖能力（

0.001）、多西他赛半抑制浓度（IC

）、葡萄糖消耗水平和乳酸生成水平（

0.001）；与inhibitor NC组比较，inhibitor组可明显增强PC-3和DU145前列腺癌细胞的增殖能力（

0.001）、葡萄糖消耗水平和乳酸生成水平（

0.001）。Starbase数据库提示miR-520a-5p与HK2和PFKM存在结合位点；免疫印迹结果显示，miR-520a-5p对HK2和PFKM的表达存在负调控关系。使用2-DG抑制前列腺癌细胞糖酵解可恢复miR-520a-5p对前列腺癌增殖能力的影响。

结论

前列腺癌中miR-520a-5p可能通过上调糖酵解关键酶HK2和PFKM表达水平增强前列腺癌细胞有氧糖酵解诱导多西他赛化疗耐药。

Abstract

Objective

To explore the effects of miR-520a-5p on the proliferation and docetaxel resistance of prostate cancer cells and the potential mechanisms.

Methods

The expression levels of miR-520a-5p in prostate cancer cells（PC-3/DU145） and normal prostate epithelial cells（RWPE-1） were measured by RT-qPCR. Western blot was used to determine whether miR-520a-5p regulated the expression of the key glycolytic enzymes hexokinase 2（HK2） and phosphofructokinase（PFKM）. The effects of miR-520a-5p on the proliferation and docetaxel resistance of prostate cancer cells were determined using cell counting kit-8. Glucose consumption and lactic acid production in the culture supernatant were assessed by enzyme-linked immunosorbent assay. According to the transfection， all cells were divided into 4 groups： minic group，minic NC group，inhibitor group and inhibitor NC group.

Results

miR-520a-5p was significantly down-regulated in prostate cancer cells（

0.001）. Compared with the mimic NC group，the mimic group showed significant decreases in the proliferative ability（

0.001），half-maximal inhibitory concentration（IC

） of docetaxel，glucose consumption level，and lactic acid production level（

0.001） of PC-3 and DU145 prostate cancer cells. Compared with the inhibitor NC group，the inhibitor group showed significantly increased proliferative ability（

0.001） and glucose consumption and lactic acid production levels（

0.001） of PC-3 and DU145 prostate cancer cells. Starbase database analysis indicated that there were binding sites between miR-520a-5p and HK2 and PFKM. Western blot results showed that miR-520a-5p negatively regulated the expression of HK2 and PFKM. Inhibiting the glycolysis of prostate cancer cells by 2-DG could recover the effect of miR-520a-5p on the proliferative ability of prostate cancer.

Conclusion

The low expression of miR-520a-5p in prostate cancer may up-regulate the key glycolytic enzymes HK2 and PFKM to enhance aerobic glycolysis，thereby inducing resistance to docetaxel in prostate cancer cells.

关键词

Keywords

references

Chang AJ ， Autio KA ， Roach M ， et al . High-risk prostate cancer-classification and therapy [J ] . Nat Rev Clin Oncol ， 2014 ， 11 （ 6 ）： 308 - 323 .

Liu JZ ， Dong L ， Zhu YJ ， et al . Prostate cancer treatment - China's perspective [J ] . Cancer Lett ， 2022 ， 550 ： 215927 .

Desai K ， McManus JM ， Sharifi N . Hormonal therapy for prostate cancer [J ] . Endocr Rev ， 2021 ， 42 （ 3 ）： 354 - 373 .

Ma ZH ， Zhang WW ， Dong BJ ， et al . Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy [J ] . Theranostics ， 2022 ， 12 （ 11 ）： 4965 - 4979 .

Barata PC ， Sartor AO . Metastatic castration-sensitive prostate cancer：Abiraterone，docetaxel，or… [J ] . Cancer ， 2019 ， 125 （ 11 ）： 1777 - 1788 .

Fabris L ， Ceder Y ， Chinnaiyan AM ， et al . The potential of microRNAs as prostate cancer biomarkers [J ] . Eur Urol ， 2016 ， 70 （ 2 ）： 312 - 322 .

Fu RB ， Shao Q ， Yang B ， et al . MiR-520a-5p/PPP5C regulation pattern is identified as the key to gemcitabine resistance in pancreatic cancer [J ] . Front Oncol ， 2022 ， 12 ： 903484 .

Xu XL ， Tao R ， Sun LY ， et al . Exosome-transferred hsa_circ_0014235 promotes DDP chemoresistance and deteriorates the development of non-small cell lung cancer by mediating the miR-520a-5p/CDK4 pathway [J ] . Cancer Cell Int ， 2020 ， 20 （ 1 ）： 552 .

Mori K ， Mostafaei H ， Sari Motlagh R ， et al . Systemic therapies for metastatic hormone-sensitive prostate cancer：network Meta-analysis [J ] . BJU Int ， 2022 ， 129 （ 4 ）： 423 - 433 .

Shi Q ， Zhu YS ， Ma J ， et al . Prostate cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly [J ] . Mol Cancer ， 2019 ， 18 （ 1 ）： 170 .

Nader R ， Amm JE ， Aragon-Ching JB . Role of chemotherapy in prostate cancer [J ] . Asian J Androl ， 2018 ， 20 （ 3 ）： 221 - 229 .

He BX ， Zhao ZY ， Cai QD ， et al . miRNA-based biomarkers，therapies，and resistance in Cancer [J ] . Int J Biol Sci ， 2020 ， 16 （ 14 ）： 2628 - 2647 .

Vazquez-Urrutia JR ， Torres-Bustamante MI ， Cerda-Cruz CR ， et al . The role of miRNA in prostate cancer diagnosis，prognosis and treatment response：a narrative review [J ] . Future Oncol ， 2023 ， 19 （ 1 ）： 77 - 93 .

Nagesh PKB ， Chowdhury P ， Hatami E ， et al . miRNA-205 nanoformulation sensitizes prostate cancer cells to chemotherapy [J ] . Cancers（Basel）， 2018 ， 10 （ 9 ）： 289 .

Zhu ZR ， Tang GL ， Yan JJ . MicroRNA-122 regulates docetaxel resistance of prostate cancer cells by regulating PKM2 [J ] . Exp Ther Med ， 2020 ， 20 （ 6 ）： 247 .

Armstrong CM ， Liu CF ， Lou W ， et al . MicroRNA-181a promotes docetaxel resistance in prostate cancer cells [J ] . Prostate ， 2017 ， 77 （ 9 ）： 1020 - 1028 .

Ahmad F ， Cherukuri MK ， Choyke PL . Metabolic reprogramming in prostate cancer [J ] . Br J Cancer ， 2021 ， 125 （ 9 ）： 1185 - 1196 .

Song CZ ， Zhang JN ， Liu X ， et al . PTEN loss promotes Warburg effect and prostate cancer cell growth by inducing FBP1 degradation [J ] . Front Oncol ， 2022 ， 12 ： 911466 .

Jiang XK ， Guo SQ ， Wang S ， et al . EIF4A3-induced circARHGAP29 promotes aerobic glycolysis in docetaxel-resistant prostate cancer through IGF2BP2/c-Myc/LDHA signaling [J ] . Cancer Res ， 2022 ， 82 （ 5 ）： 831 - 845 .

Yi Q ， Wei JF ， Li YZ . Effects of miR-103a-3p targeted regulation of TRIM66 axis on docetaxel resistance and glycolysis in prostate cancer cells [J ] . Front Genet ， 2021 ， 12 ： 813793 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

TMEM9 promotes the proliferation and invasion of prostate cancer by affecting autophagy

Association of miR-296-5p，S-phase kinase-associated protein 2， and ribosomal protein L6 with the pathological features of prostate cancer and their influence on surgical prognosis

Deleted in liver cancer-1 inhibits the proliferation and invasion of enzalutamide-resistant prostate cancer cells via the Rho pathway

Application of nanoparticles in the treatment of prostate cancer

The expression of MTAP in prostate cancer and its effect on immune cells

Related Author

Su Shuai

Zhang Jindong

Luo Yu

Song Liangdong

Liu Hengchuan

Zhu Huixuan

Wang Delin

Liu Jiaxin

Related Institution

Department of Urology，The First Affiliated Hospital of Chongqing Medical University

Urology 2nd Ward, Xinxiang Central Hospital，The Fourth Clinical College of Xinxiang Medical College

Critical Care Medicine 1st Ward, Xinxiang Central Hospital，The Fourth Clinical College of Xinxiang Medical College

Department of Urology,Guizhou Provincial People’s Hospital

Zunyi Medical University

⁰